National Talcum Powder Lawsuit After J&J’s Third Bankruptcy Collapse — What Your Claim Is Worth in 2026
If you or someone you love was diagnosed with mesothelioma or ovarian cancer after years of using talcum powder, you have been waiting. Four years of waiting, actually — while Johnson & Johnson pushed case after case into bankruptcy court, filed through subsidiaries created on purpose to wall off the liability, and told you the only path to compensation was a trust distribution that would pay pennies on the dollar. That wait is over. On March 31, 2025, a federal bankruptcy judge in Texas dismissed J&J’s third attempt — and this time, J&J announced it would not appeal. The cases are back in the trial system. And in the twelve months since that dismissal, juries have returned more than $3 billion in mesothelioma verdicts against talc defendants.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort and product liability cases for people whose lives were torn open by products they were told were safe. This page is our analysis of where talc litigation stands right now, what your claim may be worth, and what the next steps look like — written for the person reading at 2 a.m. who just got a diagnosis or just learned the bankruptcy finally failed. We are not your counsel on this case unless you call us and we sign with you. But we can tell you, in plain language, what the law is, what the evidence clock is, and what the fight looks like from the inside.
The Bankruptcy Door Is Closed — Three Filings, Three Dismissals
Here is what happened, and why it matters to you.
Johnson & Johnson spent four years trying to resolve its talcum powder liability through Chapter 11 bankruptcy. The strategy was built on a maneuver called the “Texas Two-Step” — J&J would split its consumer division into two entities: one that kept the business and one that absorbed all the cancer liability. The liability entity would then file for bankruptcy, pausing every pending lawsuit nationwide and forcing claimants into a trust-based settlement that paid a fraction of what a verdict would deliver.
The first two attempts were filed through a subsidiary called LTL Management LLC, in the District of New Jersey. Both were dismissed — the courts found the subsidiary was not in genuine financial distress and was using bankruptcy to escape litigation it could pay. The third attempt came in 2024 through a newly created entity called Red River Talc LLC, this time filed in the Southern District of Texas before Bankruptcy Judge Christopher Lopez. Red River proposed an $8 billion settlement trust and solicited votes from approximately 93,000 claimants. More than 75 percent voted to approve — the threshold required under Section 1126(c) of the Bankruptcy Code.
But on March 31, 2025, Judge Lopez issued a 57-page opinion dismissing the case anyway. The vote count may have been numerically sufficient, but the court found the solicitation process was procedurally deficient — the voting window was unreasonably short, and the solicitation irregularities were serious enough to undermine the integrity of the count. The court declined to appoint a trustee or convert the case, noting there was no real business operation to preserve.
J&J announced shortly after the dismissal that it would not appeal and would instead defend the pending cases in the tort system. For practitioners, that announcement is the operative fact.
That single sentence is the most important development in four years of talc litigation. The bankruptcy door is closed. Three filings, three dismissals, in two jurisdictions, under three different legal theories. J&J is not going to try a fourth time. The path to recovery runs through the trial system now — through individual settlements and jury verdicts, not trust distributions.
What the Tort System Has Produced Since March 2025
The trial record since the Red River dismissal is substantial. Juries have returned more than $3 billion in mesothelioma verdicts. The largest reported outcomes include a $966 million verdict in California and a $1.5 billion verdict in Baltimore. These are outlier numbers — but they are no longer freak occurrences. Compensatory awards in the $15 to $50 million range are now typical rather than exceptional in talc mesothelioma trials that reach verdict.
Beyond J&J, the non-J&J cosmetic talc defendants are also producing meaningful verdicts. A $51 million California mesothelioma verdict against Avon was affirmed on appeal in February 2026 — that is a confirmed, upheld recovery, not just a headline number. A $12.75 million verdict against Port Jervis Laboratories (Jafra cosmetics) came in March 2026. These confirm that cosmetic talc defendants beyond J&J face real trial exposure, and that cases pointing to non-J&J products can produce substantial recoveries.
The MDL-2738 docket — the federal multidistrict litigation consolidated in the District of New Jersey before District Judge Michael Shipp — now holds more than 67,000 pending cases. That docket is moving in two different procedural directions, and the track your claim falls on determines your expected timeline and resolution structure.
The Two-Track Reality: Mesothelioma Individual Trials vs. Ovarian Cancer Mediation
The most important practical observation for case evaluation is that the MDL-2738 docket operates on two tracks, and they behave differently.
The mesothelioma track runs through individual settlements and occasional trials. Historically, mesothelioma claims settled at approximately a 95 percent rate on the pre-trial docket. J&J’s post-bankruptcy public position has been that it will try more cases rather than settle — but the trial record since March 2025 shows that individual settlements remain the dominant resolution mechanism. Trials are reserved for cases where the causation or product-identification evidence particularly favors the defense. In other words, J&J picks its battles, and when it picks wrong, the verdicts are enormous.
The ovarian cancer track — which constitutes the large majority of the approximately 67,000 pending MDL cases — is on a court-ordered mediation track. The MDL court ordered court-supervised mediation in 2025 and appointed Fouad Kurdi of Resolutions LLC to structure the process. The first session was held September 4, 2025, and additional sessions have been scheduled. Whether the mediation produces a global resolution remains an open question — J&J has publicly signaled reluctance — but individual ovarian cancer trials continue to proceed in parallel. A California bellwether produced a $40 million verdict for two plaintiffs in December 2025, demonstrating that ovarian cancer trials can produce significant results even while mediation is underway.
A late-2025 order by Magistrate Judge Rukhsanah Singh narrowed the ovarian cancer track further by requiring expert support for non-ovarian gynecologic claims — endometrial, cervical, and uterine cancer claims — with both sides agreeing that the scientific support for those claims was limited. The practical effect has been a narrower but more focused ovarian cancer docket heading into mediation.
The Wolfson R&R: Why Your Ovarian Cancer Case Just Became More Valuable
A development worth understanding — because it directly affects what your ovarian cancer claim is worth — is Judge Freda Wolfson’s 658-page Report and Recommendation issued in January 2026 in her capacity as Special Master on the renewed Daubert motions.
Here is what happened in plain language. In 2020, Judge Wolfson ruled on the original Daubert motions and allowed plaintiffs’ causation experts to testify that genital talc use is linked to ovarian cancer. That ruling was a win for plaintiffs — it meant the defense could not exclude the experts who connect talc to ovarian cancer at trial. But in 2023, the federal rules changed. Congress amended Federal Rule of Evidence 702 to tighten the standards for expert testimony admissibility — making it harder to get scientific opinions in front of a jury. The defense renewed its Daubert motions, arguing that under the amended standard, the plaintiffs’ experts should now be excluded.
Judge Wolfson’s 658-page R&R evaluated whether the 2023 Rule 702 amendments and post-2020 scientific developments required reconsideration. Her conclusion: the plaintiffs’ experts are still admissible. The talc-ovarian cancer link has enough scientific support that qualified experts may testify to it at trial.
That R&R is now before District Judge Michael Shipp for adoption. If he adopts it — and there is no reason to expect he will not — it functions as a second plaintiff-side admissibility win on causation experts in this litigation. The practical effect for case valuation is significant: the primary defense strategy for depressing ovarian cancer case values was to exclude the experts who connect the disease to the product. With that strategy foreclosed by the R&R, the risk allocation shifts toward defense-side causation arguments at trial rather than gatekeeping before trial. In simpler terms: your experts get to testify. The defense has to beat them in front of a jury, not keep them out of the courthouse.
In parallel, J&J has pursued a collateral attack on plaintiff expert Dr. Jacqueline Moline, reopening a defamation action aimed at discrediting her published research on asbestos in talc. That effort has not produced any exclusion of Dr. Moline’s testimony at trial — but it tells you something about how seriously J&J takes the expert-admissibility fight. When a company files a defamation suit against a scientist whose research hurts its defense, it is not confident in the merits of its causation argument. It is trying to win by another route.
Who Can Be Sued: Johnson & Johnson and the Non-J&J Cosmetic Talc Defendants
The J&J Corporate Structure and the Texas Two-Step
Johnson & Johnson is the primary defendant in the talc litigation. The company manufactured and marketed talc-based Johnson’s Baby Powder and Shower-to-Shower products for decades. The corporate structure surrounding the talc liability is deliberately complex — and understanding it matters because it affects who you sue and where the money comes from.
The entities involved include Johnson & Johnson Consumer Inc. (the historical talc seller), LTL Management LLC (the subsidiary created for the first two bankruptcy filings, both dismissed), Red River Talc LLC (the subsidiary created in 2024 for the third bankruptcy filing, dismissed March 31, 2025), and Kenvue Inc. — the consumer health spinoff that now holds brands like Band-Aid, Tylenol, and Listerine. J&J retained indemnity obligations for talc liability when it spun off Kenvue, but Kenvue is a separate publicly traded company. The corporate structure is fluid, and the specific entity you name in a complaint depends on when and where the exposure occurred.
The Texas Two-Step strategy — splitting a company to channel liability into a bankruptcy-filing subsidiary — is now effectively dead for J&J’s talc cases. Three dismissals across two jurisdictions have established a precedent that is hostile to this liability-channeling strategy. For you, that means the real defendant is Johnson & Johnson itself, defending cases in the tort system with its own balance sheet behind them.
Non-J&J Defendants: Avon, Colgate-Palmolive, Coty, and Jafra
A separate development in the post-bankruptcy landscape is the emergence of non-J&J cosmetic talc defendants as viable standalone targets. Recent verdicts against Avon, Colgate-Palmolive (Cashmere Bouquet), Coty, and Port Jervis Laboratories (Jafra cosmetics) show that product-identification evidence pointing to non-J&J products no longer defeats a case — it shifts the defendant mix.
This matters because some claimants used multiple talc products over their lifetime. If the evidence of J&J product use is weak but the evidence of Avon or Colgate-Palmolive product use is strong, the case does not go away. It pivots. The $51 million Avon verdict — affirmed on appeal in February 2026 — confirms that these defendants face real exposure and that juries will hold them accountable. The $12.75 million Jafra verdict in March 2026 confirms that even smaller cosmetic talc suppliers are not immune.
For case evaluation, the practical question is: which products did you use, for how long, and how strong is the evidence? If J&J product identification is strong, J&J is the primary target. If it is weak, we look at every other cosmetic talc product you used and build the case against the manufacturer whose product we can prove you used.
The Medicine: How Talc Causes Cancer
Understanding the medicine is not optional in a talc case — it is the foundation of everything. The defense will challenge causation at every stage, and the family that understands what happened inside the body is the family that can sit through a trial and know the truth when they hear it.
Mesothelioma — The Signature Disease
Malignant mesothelioma is a cancer of the lining of the lungs, abdomen, or — less commonly — the heart. It is essentially specific to asbestos exposure. When a person develops mesothelioma, the disease itself points back to asbestos — it is so rare in the absence of asbestos exposure that diagnosis is near-conclusive proof of exposure to the fiber.
The mechanism is physical. Asbestos fibers — and asbestos-contaminated talc contains asbestos fibers — are inhaled or ingested and lodge in the lining of the lungs or abdomen. The body cannot clear them. Decades of chronic irritation, inflammation, and reactive oxygen species damage the mesothelial cells until malignant transformation occurs. The latency is long — typically 20 to 50 years, with most cases appearing 30 to 40 years after first exposure. A worker exposed in their twenties may not be diagnosed until retirement.
Mesothelioma is uniformly fatal. Median survival from diagnosis is 12 to 21 months. There is no cure. The disease produces complete economic damages — medical costs, lost wages, and substantial non-economic damages for pain, suffering, fear of death, and loss of life quality. The short survival window is why expedited trial settings are available in many jurisdictions for mesothelioma claimants — and it is why evidence preservation is an emergency, not a planning item. If you are reading this page because you or a loved one was just diagnosed with mesothelioma, the clock on your case and the clock on your life are running simultaneously.
For families in industrial communities — refinery workers, construction workers, shipyard workers — the mesothelioma diagnosis may involve both cosmetic talc exposure and occupational asbestos exposure. Our firm has deep experience with mesothelioma and toxic exposure cases in refinery communities, and we know how to separate the cosmetic talc pathway from the occupational pathway and build the case that accounts for both.
Ovarian Cancer — The Cleared Causation Theory
The ovarian cancer track is built on a different scientific foundation. The theory is that genital talc use — application of talcum powder to the perineal area, or use of talc-containing diaphragms or condoms — allows talc particles to travel through the reproductive tract to the ovaries, where chronic inflammation drives malignant transformation.
For years, J&J’s primary defense strategy on ovarian cancer cases was to exclude the plaintiffs’ causation experts under the Daubert standard — to argue that the science connecting talc to ovarian cancer was not reliable enough to go before a jury. That strategy has now failed twice. Judge Wolfson’s original 2020 ruling allowed the experts. Her January 2026 R&R — issued after the 2023 Rule 702 amendments tightened the standard — confirmed that the experts are still admissible. The science has enough support that qualified experts may testify to the talc-ovarian cancer link at trial.
Ovarian cancer cases typically carry lower individual values than mesothelioma cases — but they are far more numerous, constituting the large majority of the 67,000 pending MDL cases. The $40 million California bellwether verdict for two plaintiffs in December 2025 establishes a baseline for what ovarian cancer trials can produce. The value of an individual ovarian cancer case depends heavily on exposure evidence (frequency and duration of talc use), cancer severity and stage, product identification strength, and the jurisdiction where the case is filed.
What Your Talc Claim Is Worth in 2026
We cannot tell you what your specific case is worth without reviewing your medical records, your exposure history, and your product-use evidence. What we can tell you is what the trial record shows — and the trial record has shifted in ways that merit careful attention.
Mesothelioma Case Valuation
The settlement ranges that were appropriate in 2023 no longer reflect current trial risk for J&J. Compensatory awards in the $15 to $50 million range now have a substantial trial record behind them. Outlier verdicts — the $966 million California verdict, the $1.5 billion Baltimore verdict — have shown juries willing to go far higher when the evidence of corporate knowledge and concealment is strong.
Individual case value is heavily dependent on:
– Product identification strength — Can you prove you used J&J talc products? For how long? Do you have receipts, photographs, family testimony, or other corroboration?
– Exposure duration and intensity — How many years of use? Daily or occasional? Genital application or body use?
– Alternative exposure sources — For mesothelioma, was there occupational asbestos exposure? The defense will argue the cancer came from the workplace, not the powder.
– Jurisdiction — California and Maryland have produced the largest verdicts. Both apply pure comparative fault and have jury pools historically receptive to corporate accountability narratives. The filing jurisdiction directly affects both settlement leverage and trial outcome.
– Claimant demographics — Age, earning capacity, family structure, and life expectancy all feed the economic damage calculation.
Ovarian Cancer Case Valuation
Ovarian cancer cases should now be evaluated with expert admissibility as a substantially reduced risk. The Wolfson R&R — assuming adoption by Judge Shipp — forecloses much of the defense’s most viable exclusion theory and shifts the fight to defense-side causation arguments at trial rather than gatekeeping before trial.
The ovarian cancer mediation track under Fouad Kurdi provides a structured resolution path, but parallel trial preparation must continue to preserve leverage. The $40 million California bellwether demonstrates that ovarian cancer trials can produce significant verdicts. Individual case value depends on the same factors as mesothelioma — product identification, exposure duration, jurisdiction, cancer severity — with the added variable of mediation progress.
Punitive Damages — Available but Vulnerable
Punitive damages are available across most jurisdictions when plaintiffs demonstrate knowledge of asbestos contamination and deliberate concealment. The evidence of J&J’s internal knowledge — decades of testing results, internal communications about asbestos contamination, and marketing strategies that downplayed risk — is the foundation for punitive damages and fraudulent concealment theories.
But punitive damages remain vulnerable on post-trial motion, particularly where malice and prior-knowledge proofs are close. The article notes this explicitly — and it is a real risk. A jury may award nine figures in punitive damages, and a trial judge or appellate court may reduce or reverse that portion of the award. This is why over-development of the concealment evidentiary record matters: the stronger your proof that J&J knew and hid the danger, the harder it is for a court to cut the punitive component.
The Evidence Clock — What Exists, Who Holds It, How Fast It Disappears
Every talc case lives or dies on evidence, and some of that evidence is dying while you read this page. Here is what exists, who holds it, and how fast it can legally disappear.
Product identification and exposure history is the single most important battleground element for both settlement leverage and trial outcome. It is also the most perishable. Claimant health declines daily. Family recall diminishes. Mesothelioma claimants have terminal diagnoses with limited life expectancy — and when the person who used the powder passes, the ability to testify about what they used, how often, and for how long goes with them. This is why the exposure interview must happen immediately upon case intake — not next month, not when you “have time to deal with it,” but the day you call.
Tissue pathology samples — retained mesothelioma or ovarian tumor tissue — can provide specific causation evidence through forensic asbestos and talc fiber analysis. Pathology labs have retention policies that may result in tissue disposal. The retention period varies by lab and state law, but the risk is real: if the tissue is destroyed before a fiber analysis is requested, that specific causation evidence is gone. We request tissue retention immediately upon case intake.
Internal corporate documents — decades of J&J testing results, internal communications about asbestos contamination, and marketing strategies — are preserved in the MDL record. But case-specific exhibit assembly and expert review require lead time. These documents are the foundation for punitive damages and fraudulent concealment theories, and assembling the right exhibits for your specific case takes weeks of expert work.
Expert witness reports and case-specific causation analyses must be prepared as cases advance toward trial or mediation. The plaintiffs’ causation experts cleared by the Wolfson R&R must prepare case-specific reports tying your individual exposure to your diagnosis. The defense will challenge specific causation aggressively — and your expert’s report needs to be ready before that challenge arrives.
Lifetime occupational, household, and cosmetic use history documentation is the foundation of product identification. It requires extensive interviews with the claimant and family members. For mesothelioma claimants, the person may lose capacity to provide detailed history as the disease progresses. Every day that passes is a day the most important witness’s memory may fade or the witness may become unavailable.
The preservation letter — the document that orders the defendant and every relevant third party to freeze evidence — goes out the day you call us. Not the day we file suit. Not the day we finish intake. The day you call. Because the evidence that decides your case is on a clock, and the clock does not wait for you to feel ready.
The Defense Playbook — What J&J Will Try and How to Counter It
J&J has a defense playbook that has been refined across thousands of cases. Here are the plays you should expect, and how each one is countered.
Play 1: “We will try your case, not settle it.” J&J’s post-bankruptcy public posture is that it will try more cases rather than settle. The trial record since March 2025 shows this is partly bluff — individual settlements remain the dominant resolution mechanism. But the threat of trial is real, and it is designed to push claimants toward accepting less. The counter is simple: trial readiness is the primary settlement driver. The firm that prepares every case as if it will be tried is the firm that gets the best settlements. J&J settles the cases it is afraid to try.
Play 2: Expert exclusion attempts. J&J has fought for years to keep plaintiffs’ causation experts out of the courtroom. The defamation action against Dr. Moline is a collateral attack — an attempt to discredit the scientist rather than defeat the science. The counter is the Wolfson R&R itself: the experts have been cleared twice, and the 2023 Rule 702 amendments did not change that outcome. The defense now has to beat the experts in front of a jury, not keep them out of the courthouse.
Play 3: Product identification challenges. In cases where the evidence of J&J product use is weak, J&J will push for trial — betting that a jury will not connect the disease to the product without strong proof. The counter is exhaustive exposure reconstruction: every family member who can testify about what was in the bathroom cabinet, every photograph that shows the product, every receipt, every subscription. And where J&J product identification is genuinely weak, the counter is to pivot to non-J&J defendants — Avon, Colgate-Palmolive, Coty, Jafra — where the product link may be stronger.
Play 4: Alternative causation for mesothelioma. The defense will argue that mesothelioma came from occupational asbestos exposure, not cosmetic talc. For anyone who worked in construction, shipyards, refineries, or other asbestos-exposed industries, this is a serious defense. The counter is dose reconstruction — building the timeline of every exposure source and proving that cosmetic talc use was a sufficient contributing cause. The law in most jurisdictions does not require talc to be the only cause — it requires it to be a cause.
Play 5: Punitive damages post-trial motions. Even when a jury awards punitive damages, J&J will file post-trial motions to reduce or eliminate them, arguing the malice and prior-knowledge proofs were insufficient. The counter is over-development of the concealment record — the more internal documents you have showing J&J knew about asbestos contamination and said nothing, the harder it is for a court to cut the punitive award.
How a Talc Case Is Actually Built
Here is the chronological walk of how a talc case moves from intake to resolution — told by people who have run this process.
Week one: preservation and intake. The preservation letter goes out to J&J and any non-J&J defendants, ordering them to freeze all evidence relevant to your case. The exposure interview begins — hours of detailed questioning about every talc product you or your loved one ever used, when, how often, and for how long. Family members are interviewed while their memories are fresh. Medical records are requested from every treating physician, hospital, and pathology lab. Tissue retention is demanded from the pathology lab.
Weeks two through eight: record assembly and expert retention. Medical records arrive and are organized. The pathology report and tissue blocks are secured. An occupational and environmental history is built — every job, every product, every potential exposure source. Experts are retained: a causation expert to connect the talc exposure to the cancer, a life-care planner to project future medical costs, a forensic economist to calculate lost earning capacity. For mesothelioma cases, this process is accelerated because the claimant’s life expectancy is short.
Months two through six: discovery and case-specific expert reports. Written discovery is served on the defendants. Depositions are taken — of the claimant, of family witnesses, of corporate representatives. The case-specific expert reports are prepared, tying your individual exposure history to your specific diagnosis. The defense serves its own discovery and takes its own depositions. The concealment evidence — internal J&J documents showing knowledge of asbestos contamination — is assembled from the MDL record into case-specific exhibits.
Months six through eighteen: settlement negotiations and/or trial preparation. For mesothelioma cases, settlement negotiations typically begin once the case-specific expert reports are complete and the defense has evaluated the strength of the product identification and causation evidence. Cases with strong evidence command premium settlement values. Cases with weaker evidence may proceed to trial, where the outcome depends on the jury. For ovarian cancer cases, the mediation track under Fouad Kurdi provides a structured resolution path, but trial preparation continues in parallel.
Resolution. The case resolves through individual settlement, mediation outcome, or trial verdict. For mesothelioma cases, the timeline from intake to resolution is typically shorter than for ovarian cancer cases — both because the defense perceives higher trial risk and because the claimant’s limited life expectancy creates urgency. For ovarian cancer cases, the timeline depends on mediation progress and the individual court’s trial calendar.
Your First Steps — What to Do Now
If you or a loved one has been diagnosed with mesothelioma or ovarian cancer and has a history of talcum powder use, here are the steps that matter most — in order.
First: Get the medical care you need. Nothing on this page is more important than your treatment. Follow your oncologist’s plan. Get the scans, the biopsies, the chemotherapy, the surgery — whatever your medical team recommends. The legal case is built on the medical record, and the medical record is built by the doctors treating you.
Second: Write down everything you can remember about talc product use. What brands. When you started. When you stopped. How often you used it. Where you applied it. Who bought it. Where it was kept in the house. Do this now — not next week. Memory fades, and for mesothelioma claimants, the ability to provide this history may fade with the disease.
Third: Ask family members to write down what they remember. A spouse, sibling, child, or friend who can testify that they saw you use Johnson’s Baby Powder every morning for thirty years is worth more than any document. Their memory is evidence — and it is perishable.
Fourth: Request tissue retention from the pathology lab. If biopsy or surgical tissue was retained, it may contain forensic evidence of talc and asbestos fibers. Pathology labs have retention policies that can result in tissue disposal. A request to retain the tissue — in writing — should go out as soon as possible.
Fifth: Do not sign anything from J&J, any insurance company, or any claims administrator. Do not give a recorded statement. Do not accept a quick check. Do not agree to any settlement, release, or waiver without speaking to a lawyer first. The four years of bankruptcy strategy were designed to push claimants into accepting trust distributions worth a fraction of what a verdict would deliver. That pressure has not stopped — it has just changed form.
Sixth: Call a lawyer who handles toxic tort and product liability cases. Not a generalist. Not a firm that “also does” mass torts. A firm that knows the MDL-2738 docket, the Wolfson R&R, the mediation track, and the evidence clock. The consultation is free. The call costs nothing. And the day you call is the day the evidence-preservation clock starts working for you instead of against you.
The Statute of Limitations — The Discovery Rule and Your Deadline
Every state has a statute of limitations — a deadline after which you cannot file a lawsuit. For talc cases, that deadline is governed by a doctrine called the discovery rule, and it is the single most important legal concept for you to understand.
The general principle — recognized across most jurisdictions — is this:
In actions involving latent injury or disease, the cause of action does not accrue until the plaintiff has discovered, or by reasonable diligence should have discovered, the injury and its cause.
In plain language: the clock to sue does not start when you used the talcum powder. It starts when you were diagnosed with cancer — or when you reasonably should have connected your cancer to talc use. For many claimants, that date is the date of diagnosis. For others, it may be the date they first learned that talc was linked to their type of cancer.
The specific limitations period varies by state. Most states set the personal injury deadline at two to three years from the date the claim accrued (the date of discovery). Some states allow one year. Some allow longer. Wrongful death deadlines — which apply if the claimant has passed away — are typically one to three years from the date of death and are often shorter than personal injury deadlines.
Some states also impose a statute of repose — an outer deadline that can cut off a claim even before discovery. The discovery rule does not defeat a repose statute. If your state has one, it may bar your claim regardless of when you discovered the connection.
We cannot tell you your specific deadline without knowing your state, your diagnosis date, and your exposure history. What we can tell you is this: the deadline is real, it is unforgiving, and it is shorter than most people think. If you are reading this page and wondering whether you still have time, the safest move is to call today and let us check the deadline for your state. The call is free. The cost of missing the deadline is everything.
Why Attorney911
Ralph Manginello has spent 27-plus years in courtrooms, including federal court in the Southern District of Texas — the same district where Judge Lopez dismissed J&J’s third bankruptcy. He was a journalist before he was a lawyer, which means he reads corporate documents the way they were meant to be read: critically. He knows what a company’s own internal testing memos look like when they are laid out in front of a jury, and he knows how to build the story that connects a bottle of baby powder in a bathroom cabinet to a cancer diagnosis decades later.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims from people exactly like you. He sat in the meetings where defense lawyers mapped out the playbook: the lowball settlement offer, the expert challenge, the recorded-statement trap, the motion to exclude. He knows how the other side prices a claim, because he was the other side. Now he sits on your side of the table. And he conducts full consultations in Spanish, without an interpreter, because the family that prays in Spanish deserves a lawyer who speaks it too.
We work on contingency. That means: we do not get paid unless we win your case. The fee is 33.33 percent if the case resolves before trial, 40 percent if it goes to trial. The consultation is free. The first call costs nothing. And the first thing we do — the day you call — is send the preservation letter that freezes the evidence before it disappears.
We have recovered more than $50 million for our clients across the cases we have handled. Past results depend on the facts of each case and do not guarantee future outcomes. But the $50 million is not the point. The point is that we know how to build a case, freeze the evidence, and fight the company — and we know how to do it for people who are sick, scared, and up against one of the largest corporations in the world.
If you are considering a talc claim — for yourself, for a parent, for a spouse, for a child who lost their mother — the question is no longer whether the bankruptcy strategy will succeed. It failed. Three times. The question is how to allocate resources across mesothelioma cases that are being tried individually and ovarian cancer cases that are in mediation with a substantially cleaner expert record. We can help you answer that question.
Call us at 1-888-ATTY-911 (1-888-288-9911). The consultation is free. No fee unless we win. 24/7 live staff — not an answering service.
Hablamos Español.
This page is legal information, not legal advice. Contacting the firm is free and confidential. You should not act on any information here without specific legal advice based on your particular situation.
Frequently Asked Questions
What does the dismissal of J&J’s third bankruptcy mean for my talc case?
It means the bankruptcy door is closed and your case proceeds in the trial system. J&J announced it would not appeal the March 31, 2025 dismissal and would defend cases through individual settlements and verdicts. There will be no trust distribution. Your case is worth what a jury says it is worth — or what J&J is willing to pay to avoid a jury.
How much is my talc mesothelioma case worth?
Mesothelioma case values have moved up significantly since the bankruptcy dismissal. Compensatory awards in the $15 to $50 million range now have a substantial trial record behind them, with outlier verdicts exceeding $900 million. Individual case value depends on product identification strength, exposure duration, jurisdiction, claimant demographics, and the strength of the concealment evidence. Settlement ranges that were appropriate in 2023 no longer reflect current trial risk.
How much is my talc ovarian cancer case worth?
Ovarian cancer case values depend heavily on exposure evidence, cancer severity, product identification strength, and jurisdiction. The $40 million California bellwether verdict for two plaintiffs in December 2025 establishes a baseline for what ovarian cancer trials can produce. The Wolfson R&R’s clearance of causation experts substantially reduces the admissibility risk that previously depressed ovarian cancer valuations. Cases are being evaluated through the court-ordered mediation track under Fouad Kurdi of Resolutions LLC.
Is it too late to file a talc lawsuit?
The deadline to file depends on your state’s statute of limitations and when you discovered — or should have discovered — that your cancer was connected to talc use. Under the discovery rule, which most states apply in toxic tort cases, the clock often starts at diagnosis, not at exposure. If you were recently diagnosed, you may still have time. But the deadline is real and unforgiving. Call us and we will check the deadline for your state — the call is free.
Can I still file a claim if I used non-J&J talc products?
Yes. Recent verdicts against Avon ($51 million, affirmed on appeal February 2026), Colgate-Palmolive (Cashmere Bouquet), Coty, and Port Jervis Laboratories/Jafra cosmetics ($12.75 million, March 2026) show that non-J&J cosmetic talc defendants face real trial exposure. If your evidence of J&J product use is weak but you used Avon, Colgate-Palmolive, or other cosmetic talc products, the case does not go away — it shifts to the manufacturer whose product you can prove you used.
What is the difference between the mesothelioma track and the ovarian cancer track in MDL-2738?
Mesothelioma claims are resolved through individual settlements and occasional trials, with a historical settlement rate of approximately 95 percent on the pre-trial docket. Ovarian cancer claims — the large majority of the 67,000 pending MDL cases — are on a court-ordered mediation track under Fouad Kurdi of Resolutions LLC, with the first session held September 4, 2025. Individual ovarian cancer trials continue in parallel with the mediation. A late-2025 order by Magistrate Judge Rukhsanah Singh narrowed the ovarian cancer track by requiring expert support for non-ovarian gynecologic claims.
What is the Wolfson R&R and why does it matter for my ovarian cancer case?
Judge Freda Wolfson, serving as Special Master, issued a 658-page Report and Recommendation in January 2026 evaluating whether the 2023 amendments to Federal Rule of Evidence 702 required reconsideration of the 2020 Daubert rulings that allowed plaintiffs’ causation experts to testify on the talc-ovarian cancer link. Her conclusion: the experts are still admissible. The R&R is now before District Judge Michael Shipp for adoption. If adopted, it forecloses the defense’s primary strategy for excluding causation experts and shifts the fight to defense-side causation arguments at trial. This substantially reduces the admissibility risk that previously depressed ovarian cancer case values.
What if my loved one has already passed away from mesothelioma or ovarian cancer?
Wrongful death claims may be pursued by the personal representative of the estate or by statutory beneficiaries — typically the spouse and children, sometimes parents — depending on the state. The statute of limitations for wrongful death is typically shorter than for personal injury — often one to three years from the date of death. If your loved one passed away recently, call us immediately. The deadline for wrongful death claims is shorter and more unforgiving than most people realize. We handle wrongful death cases and can guide you through the appointment of a personal representative and the filing process.
How long does a talc case take to resolve?
For mesothelioma cases, the timeline from intake to resolution is typically shorter than for ovarian cancer cases — both because the defense perceives higher trial risk and because the claimant’s limited life expectancy creates urgency. Many mesothelioma cases resolve within months of intake. For ovarian cancer cases, the timeline depends on mediation progress, the individual court’s trial calendar, and the complexity of the exposure reconstruction. Some cases resolve in months; others take a year or more.
Do I need a lawyer, or can I handle this myself?
You need a lawyer. Not because we want your business — because J&J has a team of lawyers who have been fighting these cases for years, who know every defense play, and who are paid to pay you as little as possible. The MDL-2738 docket, the Wolfson R&R, the mediation track, the Singh order, the evidence clock, the discovery rule, the product identification requirements — this is not a system designed for self-represented claimants. The consultation is free. The fee is contingency. You have nothing to lose by calling and everything to lose by trying to handle it alone.
What does it cost to hire Attorney911 for a talc case?
Nothing upfront. We work on contingency — 33.33 percent if the case resolves before trial, 40 percent if it goes to trial. We do not get paid unless we win your case. The consultation is free. The first call costs nothing. We advance the costs of the case — filing fees, expert fees, record retrieval — and those costs are repaid from the recovery. If there is no recovery, you owe us nothing for our time.